CompletedPhase 1NCT01638533
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Roisin M ConnollyJHU Sidney Kimmel Comprehensive Cancer Center LAO
- Intervention
- Pharmacological Study(other)
- Enrollment
- 37 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2020
Study locations (12)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
- Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Case Western Reserve University, Cleveland, Ohio, United States
- Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
- University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Collaborators
Celgene Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01638533 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07402109CBCT Guided Markerless SBRT for Renal Cell CancerErasmus Medical Center
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
See all trials for Acquired cystic disease-associated renal cell carcinoma →